ライフサイエンスコーパス: tumor suppressor activity

1 of DLC1 with focal adhesions and attenuates tumor suppressor activity.

2 wnregulated in breast cancer samples and has tumor suppressor activity.

3 as a loss-of-function mutation, lacking any tumor suppressor activity.

4 x 1 (mTORC1) as a novel mediator of merlin's tumor suppressor activity.

5 ventional PcG complex can also have a potent tumor suppressor activity.

6 ing regulation by RBM5 may contribute to its tumor suppressor activity.

7 neity, a function that may contribute to its tumor suppressor activity.

8 en shown to regulate DNA methylation and has tumor suppressor activity.

9 ession of STAT1, a transcription factor with tumor suppressor activity.

10 dicate that TrkC is an inhibitor of TGF-beta tumor suppressor activity.

11 activity is required for full DLC-dependent tumor suppressor activity.

12 gulators of the circadian clock that display tumor suppressor activity.

13 ignancies in which ARF holds p53-independent tumor suppressor activity.

14 itional FOXP3 targets may be involved in its tumor suppressor activity.

15 otein phosphatase 2A (B56gamma-PP2A) and p53 tumor suppressor activity.

16 Conversely, PP2A has tumor suppressor activity.

17 tial gene regulation may contribute to IRF-1 tumor suppressor activity.

18 ncogenic tyrosine kinases can block TGF-beta tumor suppressor activity.

19 in mouse xenografts, confirming its in vivo tumor suppressor activity.

20 vin) is a multivalent anchoring protein with tumor suppressor activity.

21 ates 15-PGDH to have functional colon cancer tumor suppressor activity.

22 is likely to be an important feature of its tumor suppressor activity.

23 g whether tazarotene might activate putative tumor suppressor activity.

24 teresting possibility that hTID1 could exert tumor suppressor activity.

25 n by exerting a more general Env-independent tumor suppressor activity.

26 on of telomerase may contribute to the BRCA1 tumor suppressor activity.

27 nes in the contig had neither metastasis nor tumor suppressor activity.

28 pendent functions that may contribute to its tumor suppressor activity.

29 been studied primarily in the context of its tumor suppressor activity.

30 tic leukemia, implying that G0S2 may possess tumor suppressor activity.

31 tant defective for TAF(II)250 interaction or tumor suppressor activity.

32 th regulatory functions and causes a loss of tumor suppressor activity.

33 on of tuberin is associated with loss of its tumor suppressor activity.

34 mors and thus represents a bona fide in vivo tumor suppressor activity.

35 KT/NF-kappaB pathway may be important to its tumor suppressor activity.

36 cogene that mainly functions to modulate p53 tumor suppressor activity.

37 e central third of APC is sufficient for its tumor suppressor activity.

38 nd cell - matrix interactions are due to its tumor suppressor activity.

39 Moreover, ACTN4 exhibits tumor suppressor activity.

40 ed by homozygous deletions and by functional tumor suppressor activity.

41 lacks Ap(3)A hydrolase activity but retains tumor suppressor activity.

42 inding protein, both of which have potential tumor suppressor activity.

43 on of Rap-1, a small G-protein that exhibits tumor suppressor activity.

44 anoma gene (INK4a/MTS1/CDKN2) encodes potent tumor suppressor activity.

45 tion domain of p53 is required for efficient tumor suppressor activity.

46 s-Erk pathway likely contributes to merlin's tumor suppressor activity.

47 the functional axis can exhibit significant tumor suppressor activity.

48 inating enzyme BAP1 is deterministic for its tumor suppressor activity.

49 and Trps1, show synthetic haploinsufficient tumor suppressor activity.

50 to how these mutations interfere with APC's tumor suppressor activity.

51 he complex have been shown to have bona fide tumor suppressor activity.

52 al and lower tumor grade consistent with its tumor suppressor activity.

53 nidentified role for 53BP1 in regulating pRb tumor suppressor activity.

54 ranscription near DSBs may contribute to its tumor suppressor activity.

55 M2, a lysine methyltransferase with putative tumor suppressor activity.

56 pic changes, which may contribute to loss of tumor suppressor activity.

57 3-dependent translation, thus blocking their tumor suppressor activity.

58 ls, which may constitute the basis for their tumor suppressor activity.

59 t is not sufficient to account for, merlin's tumor suppressor activity.

60 cts of cancer-derived KLF6 mutants that lack tumor suppressor activity.

61 omes, which may confer autophagy-independent tumor suppressor activity.

62 is necessary but not sufficient for its full tumor suppressor activity.

63 mit aberrant self-renewal contributes to its tumor suppressor activity.

64 afts, while a subset had clinically relevant tumor-suppressor activity.

65 th eIF4G for binding to eIF4E and which have tumor-suppressor activity.

66 ich TrkC, a neuronal receptor, can block BMP tumor-suppressor activity.

67 rf locus, p16(INK4a) and p19(ARF), possesses tumor-suppressor activity.

68 and molecular partners necessary for merlin tumor-suppressor activity.

69 cells without del(13q), suggesting important tumor-suppressor activity.

70 t growth inhibitory effect by modulating p53 tumor-suppressor activity.

71 estoration of p53ER(TAM) allele triggers p53-tumor-suppressor activity.

72 Such a trait has been hypothesized to confer tumor-suppressor activity.

73 ITGA7 lacking TIMP3 binding activity had no tumor-suppressor activity.

74 Mdm2 is the major negative regulator of p53 tumor-suppressor activity.

75 diversity and determining why Rb has unique tumor suppressor activities.

76 mammals that supports p53 function and other tumor suppressor activities.

77 s or, alternatively, they may have redundant tumor suppressor activities.

78 functioning as an apoptotic effector of p53 tumor suppressor activities.

79 y for both cell-intrinsic and cell-extrinsic tumor suppressor activities.

80 y interact with Notch-mediated oncogenic and tumor-suppressor activities.

81 inhibitors, p16(INK4A) and p15(INK4B), have tumor suppressor activities and are inactivated in human

82 uence innate immune responses as part of its tumor suppressor activities and recent work suggests tha

83 ese mutant p53s have both lost wild-type p53 tumor suppressor activity and gained functions that help

84 ivation of HAI-2/SPINT2, causing loss of RCC tumor suppressor activity and implicate abnormalities of

85 These data suggest that BCSC-1 may exert a tumor suppressor activity and is a likely target of the

86 ata strongly suggest that wildtype Kras2 has tumor suppressor activity and is frequently lost during

87 tivation of Rap1, a protein known to exhibit tumor suppressor activity and mediate growth inhibitory

88 Loss of expression reduces tumor suppressor activity and promotes genomic instabili

89 ing of the PTEN mutants effectively restores tumor suppressor activity and represses excess PIP3 sign

90 d p53 proteins that have both lost wild-type tumor suppressor activity and show gain of functions tha

91 These results indicate that MTAP has tumor suppressor activity and suggest that its effects m

92 mutant p53 proteins that have lost wild-type tumor suppressor activity and, in many cases, have acqui

93 The loss of tumor-suppressor activity and gain of invasiveness from

94 ons in the TIP30 gene may abolish its native tumor-suppressor activity and gain oncogenic activities

95 our results show that IFIXalpha1 possesses a tumor-suppressor activity and suggest IFIXalpha1 may be

96 degrades prostaglandin E(2), appears to have tumor suppressor activity, and can be induced both by pe

97 gion 1A (E1A) has been shown to exhibit high tumor suppressor activity, and gene therapy using E1A ha

98 enforced expression of miR-19a overrides APC tumor suppressor activity, and knockdown of miR-19a in c

99 developmentally regulated gene with putative tumor suppressor activity, and loss of H19 expression ma

100 Lysyl oxidase in addition has tumor suppressor activity, and phenotypic reversion of t

101 soforms have abolished or severely decreased tumor suppressor activity, and therefore, an increase in

102 induce apoptosis has been termed "intrinsic tumor suppressor activity," and reactivating this apopto

103 suppressed by cGAS/STING knockout, and p53's tumor suppressor activities are compromised by the loss

104 OXC6 regulates genes with both oncogenic and tumor suppressor activities as well as several genes suc

105 Dimerization has a direct impact on ING4 tumor suppressor activity because monomeric mutants lose

106 Consistent with its tumor-suppressor activity, BRCA2 plays an important role

107 and produce proteins that lack canonical p53 tumor suppressor activities but promote cancer cell prol

108 The p53 protein has not only important tumor suppressor activity but also additional immunologi

109 of a cancer cell not only by absence of p53 tumor suppressor activity but also by the presence of an

110 The protein kinases Mst1 and Mst2 have tumor suppressor activity, but their mode of regulation

111 248W and R273H), not only lose p53-dependent tumor-suppressor activities, but also acquire new oncoge

112 bers of this family are capable of potential tumor suppressor activity by gene dosage or other epigen

113 gest the possibility that Fhit may exert its tumor suppressor activity by interacting with microtubul

114 6gamma interaction and the modulation of p53 tumor suppressor activity by PP2A.

115 gene signature, suggesting that CUX1 exerts tumor suppressor activity by regulating proliferative ge

116 ty, which is required for full DLC-dependent tumor suppressor activity, can be inhibited by the Src h

117 atient-derived ATL lines demonstrated strong tumor-suppressor activity characterized by reduced proli

118 mplexing Fhit mutants show reduction of Fhit tumor suppressor activity, confirming that substrate bin

119 Alternatively, E-cadherin tumor suppressor activity could result from binding and

120 a chromatin remodelling-complex subunit with tumor suppressor activity, could be conditionally inacti

121 PTEN tumor-suppressor activity depends largely on its lipid p

122 lignant gliomas, 60%-80% show loss of P14ARF tumor suppressor activity due to somatic alterations of

123 r results indicate that wild-type N-ras has "tumor suppressor" activity, even in the absence of its o

124 ly member, and ongoing studies show that its tumor suppressor activity extends beyond protease inhibi

125 nce has led to the suggestion of a potential tumor suppressor activity for IkappaBalpha, we have stud

126 des HDM2, which may define a p53-independent tumor suppressor activity for p14ARF.

127 ng chemotherapy with agents that promote p27 tumor suppressor activity for the treatment of osteosarc

128 y the Kruppel-like factor KLF2, suggesting a tumor suppressor activity for this factor.

129 PML, a RING finger protein with tumor suppressor activity, has been implicated in the pa

130 zation of a novel mitochondrial protein with tumor suppressor activity, henceforth designated MITOSTA

131 ble allele of Las2, resulting in the loss of tumor suppressor activities in both cell colony formatio

132 , and AKT kinases to reduce DLC1 Rho-GAP and tumor suppressor activities in cancer cells, which can b

133 NOTCH has tumor suppressor activities in epithelial cells and is a

134 elicits oncogenic activities in melanoma and tumor suppressor activities in nonmalignant skin cancer.

135 Mn-SOD has tumor suppressor activity in a wide variety of tumors an

136 SIRT2 is a protein deacetylase with tumor suppressor activity in breast and liver tumors whe

137 The maspin protein has tumor suppressor activity in breast and prostate cancers

138 of S100B to p53 down-regulates wild-type p53 tumor suppressor activity in cancer cells such as malign

139 stinal stem cell marker, is known to exhibit tumor suppressor activity in colon cancer, the mechanism

140 Thus, Dnmt1 has tumor suppressor activity in early-stage prostate cancer

141 The alpha 6 beta 4 integrin appears to have tumor suppressor activity in epithelial tumors.

142 3 and potentiates TGF-beta signaling and its tumor suppressor activity in gut epithelial cells.

143 ine (SCC22B) revealed its ability to provide tumor suppressor activity in HNSCC in vitro and in vivo.

144 the first time not only that C/EBPalpha has tumor suppressor activity in HNSCC, but also that it is

145 METTL3 also enhances p53 tumor suppressor activity in in vivo mouse cancer models

146 le arrest and adipocyte differentiation; has tumor suppressor activity in liposarcoma, lung, and pros

147 that p53 homologues do not contribute to p53 tumor suppressor activity in lymphoma development.

148 stages and lineages likely contribute to the tumor suppressor activity in MDS and AML.

149 to mitochondria exerts a significant in vivo tumor suppressor activity in p53-null lymphomas.

150 t the therapeutic relevance of rescuing PP2A tumor suppressor activity in Ph1 leukemias and strongly

151 first direct evidence that PKCalpha exhibits tumor suppressor activity in the lung in vivo.

152 show that the endogenous TGF-beta system has tumor suppressor activity in the mammary gland and lung.

153 ing growth factor-beta (TGF-beta) system has tumor suppressor activity in the mammary gland, we have

154 ro, the R175L mutant displayed an attenuated tumor suppressor activity in the regulation of transcrip

155 3p21.3 120-kb chromosomal region may exhibit tumor suppressor activity in vitro and in vivo.

156 ial downstream targets of PKCalpha-dependent tumor suppressor activity in vitro and in vivo.

157 have shown for the first time that BAP1 has tumor suppressor activity in vivo by showing that BAP1 c

158 t mitochondrial program exerts a significant tumor suppressor activity in vivo.

159 in malignant melanoma (MM) and restores p53 tumor suppressor activity in vivo.

160 rostaglandin dehydrogenase (PGDH), which has tumor-suppressor activity in lung, colon, breast, and ga

161 ng growth factor-beta (TGF-beta) pathway has tumor-suppressor activity in many epithelial tissues.

162 TFF2 has tumor-suppressor activity in the mouse pancreas and prev

163 by seven orders of magnitude, did not block tumor-suppressor activity in vivo, we determined whether

164 t that overexpression of MnSOD may exert its tumor suppressor activity, in part, by modulation of spe

165 t least two of these genes have evidence for tumor suppressor activity including the transcription fa

166 he steady-state level of DLC1 protein, whose tumor suppressor activity is further increased by AKT an

167 pRb tumor suppressor activity is governed by a variety of po

168 However, IRF-4 tumor suppressor activity is lost in IRF association dom

169 These results indicate that pRB's tumor suppressor activity is not effectuated by active s

170 er, the mechanism by which merlin exerts its tumor suppressor activity is not well understood.

171 These findings demonstrate that p53 tumor suppressor activity is reduced by DNA-binding doma

172 The mechanism of Fus1 tumor suppressor activity is unknown.

173 CKS, a major protein kinase C substrate with tumor suppressor activity, is likely the rodent ortholog

174 While the SWI/SNF complex displays potent tumor suppressor activity, it is unknown whether this ac

175 However, RB's tumor suppressor activity, like RB's requirement in anim

176 Unexpectedly, the tumor suppressor activity mapped to the LOX-PP domain, w

177 Modulation of tumor suppressor activities may provide new opportunitie

178 ient and control tumors suggests that TRIM14 tumor suppressor activity may depend on cell death signa

179 d mitochondrial apoptosis independent of its tumor suppressor activity mediated by AMPK and SIK.

180 liver cancer, which is the neutralization of tumor suppressor activities of an RNA binding protein, C

181 nd Bard1/Brca1-mutant mice indicate that the tumor suppressor activities of both genes are mediated t

182 xenograft model, due to reactivation of the tumor suppressor activities of DLC1.

183 like p53 (-/-) state lacks the prototypical tumor suppressor activities of p53 such as apoptosis but

184 The tumor suppressor activities of RUNX1 and RUNX3 are media

185 High levels of Smad3 are required for the tumor suppressor activities of TGF-beta, whereas lower l

186 d a lack of in vitro but significant in vivo tumor suppressor activity of 15-PGDH via an antiangiogen

187 Thus, we conclude that the tumor suppressor activity of AP2alpha is mediated throug

188 Our findings suggest that the tumor suppressor activity of Bin1 reflects engagement of

189 The tumor suppressor activity of BRCA1 may require the parti

190 ntenance of genomic integrity as a principal tumor suppressor activity of BRCA1.

191 These observations suggest that the tumor suppressor activity of caspase-2 is linked to its

192 To show tumor suppressor activity of CYGB, we performed the foll

193 inds talin and FAK, is required for the full tumor suppressor activity of DLC1 and contributes to the

194 e Fhit-Ap(3)A complex, which may enhance the tumor suppressor activity of Fhit.

195 The tumor suppressor activity of GPx3 seems to relate to its

196 This effect could contribute to the tumor suppressor activity of HINT1.

197 Env proteins cause cancer by inhibiting the tumor suppressor activity of Hyal2.

198 provides a mechanism to explain in part the tumor suppressor activity of ICSBP, since ICSBP-deficien

199 In this issue of Blood, Song et al show that tumor suppressor activity of Ikaros is achieved though r

200 ork in the authors' laboratory has shown the tumor suppressor activity of IRF-1 expression and the on

201 in human and murine HCC and uncover a novel tumor suppressor activity of KLF6 in HCC by linking its

202 approach to investigate the mechanism of the tumor suppressor activity of lysyl oxidase.

203 These data suggest that the tumor suppressor activity of maspin may depend in large

204 indings reveal, for the first time, that the tumor suppressor activity of miR-124 could be partly due

205 portantly, this is the same region where the tumor suppressor activity of myopodin is located.

206 development, we systematically surveyed for tumor suppressor activity of Notch1 in vivo.

207 phorylation at conserved sites regulates the tumor suppressor activity of Numb.

208 The tumor suppressor activity of P14ARF is in part a result

209 rtant nongenotoxic stress that modulates the tumor suppressor activity of p53 during malignant progre

210 The tumor suppressor activity of p53 is regulated by interac

211 rotein degradation, while correctors restore tumor suppressor activity of p53 mutants by enhancing th

212 Here, we report that a noncanonical tumor suppressor activity of p53 prevents cardiac dysfun

213 -dependent apoptosis and interferes with the tumor suppressor activity of p53.

214 proapoptotic functions are essential for the tumor suppressor activity of p53.

215 n of the G2 checkpoint may contribute to the tumor suppressor activity of p53.

216 Because of the ubiquitous expression and tumor suppressor activity of PP2A in cells, as well as t

217 ic Chk1 activity in cancer cells induced the tumor suppressor activity of protein phosphatase protein

218 of cyclin B1 and suggest a link between the tumor suppressor activity of ptc1 and the regulation of

219 e that Tag might not be fully inhibiting the tumor suppressor activity of Rb.

220 Reciprocating the anti-estrogenic tumor suppressor activity of RUNX proteins, inhibition o

221 but interactive pathways that inactivate the tumor suppressor activity of Schwannomin to allow prolif

222 Collectively, our findings suggest that the tumor suppressor activity of SIRT2 requires its ability

223 ired Mad activity in Drosophila or decreased tumor suppressor activity of Smad4/DPC4 in pancreas canc

224 We demonstrate that the tumor suppressor activity of Snf5 depends on its regulat

225 increased tumorigenicity in vivo indicating tumor suppressor activity of TGFbeta signaling in this m

226 Thus, tumor suppressor activity of the BMPs in skin epithelium

227 The tumor suppressor activity of the BRCA1 gene product is d

228 As a first step in evaluating the tumor suppressor activity of the manganese superoxide di

229 In the present study, we examined the tumor suppressor activity of the prohibitin 3'UTR in hum

230 ibited tumorigenesis, further supporting the tumor suppressor activity of this miRNA.

231 ntegrating metabolic effects of THs with the tumor suppressor activity of THRB, the effect of thyroid

232 These results suggest that the tumor suppressor activity of TMEFF2 requires the cytopla

233 e a possible mechanistic explanation for the tumor suppressor activity of WTX.

234 the view that p16INK4a and p19ARF exert the tumor-suppressor activities of this locus, although thei

235 s disrupted the subcellular localization and tumor-suppressor activity of PTEN.

236 The tumor-suppressor activity of the retinoblastoma protein

237 nscript map, important in the elucidation of tumor suppressor activity on chromosome 11p15.5.

238 cts of cancer-derived KLF6 mutants that lack tumor suppressor activity.Oncogene advance online public

239 However, the mechanism of myopodin tumor-suppressor activity or signaling that leads to act

240 tion, and that several NF2 mutants that lack tumor-suppressor activity present improper localization.

241 Factors that mediate p53 tumor suppressor activity remain largely unknown.

242 E7 oncoproteins that antagonize p53 and pRB tumor suppressor activity, respectively.

243 Besides losing tumor suppressor activity, some hotspot p53 mutants gain

244 repressed by Myc include several with potent tumor suppressor activity such as miR-15a/16-1, miR-34a,

245 as Ras and RhoA inhibit, whereas genes with tumor suppressor activity such as RhoB enhance NOS2 indu

246 n and deletion, including genes that exhibit tumor-suppressor activity, such as CISH1 (encoding SOCS1

247 ced ITGA7-TIMP3 signaling and the downstream tumor-suppressor activity, suggesting the existence of a

248 In addition, lysyl oxidase has tumor suppressor activity that has been shown to depend

249 tory subunit of ribonucleotide reductase has tumor suppressor activity that is mediated through effic

250 invasion of colon carcinoma cells indicating tumor suppressor activity that is unrelated to protease

251 Unc5c, encodes a pro-apoptotic receptor with tumor suppressor activity that we found is negatively re

252 we show that in addition to inactivating p53 tumor suppressor activities, the Tag-p53 complex has gro

253 ain a wild-type gene but exhibit reduced p53 tumor suppressor activity through overexpression of the

254 l, Kim et al. identify WTX modulation of p53 tumor-suppressor activity through regulation of p53 acet

255 ogether, our findings ascribe INK4a's potent tumor suppressor activity to the cooperative actions of

256 nvolved, at least in some cell types, in the tumor suppressor activity triggered after inappropriate

257 effects on MBNL1 may therefore, yield potent tumor suppressor activities, uncovering new therapeutic

258 uppressor, but a mouse model for testing the tumor suppressor activity was missing.

259 lipid phosphatase-dependent and -independent tumor suppressor activities, we investigated the contrib

260 gate the molecular and cellular basis of BHD tumor suppressor activity, we generated mutant Bhd mice

261 The target genes mediating this tumor suppressor activity were unknown.

262 ontroversial as some findings have suggested tumor suppressor activity while other studies have shown

263 tide (LOX-PP) domain of secreted pro-LOX has tumor-suppressor activity, while the active enzyme promo

264 he two proteins (Adp14/p53) and compared its tumor suppressor activity with that of a single gene vec